MV TELEGRAPH

Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, speaks to Alex Azar, the unpictured Secretary for Health and Human Services (HHS), before receiving the Cova-19 vaccine from Moderna Inc. during an event at the NIH Clinical that Center Masur Auditorium in Bethesda, Maryland, the United States, on Tuesday, December 22, 2020. The National Institutes of Health are hosting a livestream vaccination event to kickstart the organization’s efforts for its workers on the front lines of the pandemic. Photographer: Patrick Semansky / Associated Press / Bloomberg via Getty Images

Bloomberg | Bloomberg | Getty Images

According to Dr. Anthony Fauci, director of the National Institute of Allergies and Infectious Diseases, was disappointing with the slower-than-expected adoption of Covid vaccines in the US.

Officials from Operation Warp Speed, President Donald Trump’s vaccination program, said the country would immunize 20 million people with the first of the two Covid-19 vaccines in December. According to the Centers for Disease Control and Prevention, of more than 12.4 million doses distributed, nearly 2.8 million were actually administered.

“We would have liked to see it go smoothly and have 20 million doses administered to people by the end of 2020 (year). That was the projection. Obviously it didn’t and that’s disappointing,” Fauci said Thursday on NBCs ” TODAY “show. “Hopefully the increasing momentum in the first few weeks of January will get us to where we want to be.”

States and counties need more resources to speed up the pace of vaccination, Fauci said. Trump has been defending his administration’s rollout for the past few days, saying it is the responsibility of states to manage the shots as soon as they are delivered by Operation Warp Speed.

Michael Pratt, a spokesperson for the program, said earlier this week that the CDC’s data is likely to be incorrect due to delays in reporting.

“Operation Warp Speed ​​remains on track to deliver approximately 40 million vaccine doses and 20 million primary vaccination doses by the end of December 2020. The distribution of the 20 million primary doses extends into the first week of January when states place orders she, “he said in a statement.

Dr. Paul Offit, director of the Vaccine Education Center at Pennsylvania Children’s Hospital, told CNN Thursday that the federal government had invested heavily in vaccine development, but had failed to meet those efforts in terms of distribution and administration.

“With the urgency we put into making a vaccine and the money we put into making a vaccine, we spent $ 24 billion on what was essentially a Manhattan Project-style response. .. That’s the vaccine part, “he said. “Now comes the vaccination part that is just as difficult and will equally require this Manhattan Project-like response.”

“The federal government needs to step up its response to vaccination in the same way that it stepped up its response to making the vaccine,” said Offit, a voting member of the Food and Drug Administration’s Advisory Committee on Vaccines and Related Biological Products.

Dr. Jonathan Reiner, professor of medicine and surgery at the George Washington University School of Medicine and Health, calls for “mass vaccination” events. He said the government should consider converting places like polling stations, soccer stadiums and race tracks into temporary vaccination clinics.

“We have to vaccinate about 2 million people a day … versus 150,000 people a day. And I just don’t see the urgency,” he told CNN on Thursday.

Also on Thursday, New York City Mayor Bill de Blasio said the city would use schools, pop-up clinics and “whatever it takes” to deliver 1 million vaccinations by the end of January. “We have to switch to mass vaccination mode and we have to do that now.”

Tech investor Gene Munster told CNBC Thursday that he saw a sensible path for Apple to reach a future market cap of $ 3 trillion.

The iPhone maker was the first publicly traded US company to reach a market capitalization of $ 2 trillion in August – a milestone that Munster anticipated in January when he advocated its stock trading 50% higher. As of Thursday, Apple was valued at nearly $ 2.3 trillion at roughly $ 133 per share.

Munster, who reported to Apple as a longtime analyst at investment bank Piper Jaffray, said on Squawk Box that he believes the California-based company can realistically hit $ 200 per share. That would put the market cap over $ 3 trillion.

“It has to be anchored in the result. This is the powerful piece of Apple history,” said Munster, co-founder of venture capital firm Loup Ventures. He said his forecast was based on Apple trading in value for money, or a multiple of 35, for earnings estimates for 2022.

“It’s a year out there, but I’m fast forwarding the conversation to the middle and back half of next year, and at that point we’ll be talking about 2022. If the market can take those 35 multiples – you know, we’re talking.” here not by an Amazon-like multiple – I think that this path is there, “said Münster.

Apple’s current price-to-earnings ratio is close to 41, after its stock rose 81% this year. Amazon, whose shares are up 76% this year, is trading 95 times.

One catalyst that could help push Apple further is the greater spread of remote working that is being triggered by the coronavirus pandemic, Munster said.

“This is generally seen as a game on the iPhone, a 5G game. That is good. That will have a positive effect on the numbers, but I think this acceleration of the digital transformation is powerful,” said Münster. “People who work from anywhere will upgrade and buy more Macs, iPads and services in the next 12 to 24 months.”

Munster also reiterated his belief that Apple’s multiples could withstand further expansion as investors rethink the company, which in recent years has been pushing to generate more revenue from services to increase hardware sales.

Munster, for his part, said Apple could use its hardware business for a service, such as buying a Mac by subscription. “We believe this is coming, and talking more about cars is a great opportunity for Apple’s multiples,” Munster said, alluding to reports that Apple may be making an electric car in a few years.

More broadly, he said he believes Apple will continue its strong stock performance into 2021, especially when compared to its so-called FAANG brothers. In addition to Apple, the group of technology companies also includes Amazon, Facebook, Google’s parent alphabet and Netflix.

“We believe there will be another break from FAANG,” said Münster, with Facebook and Netflix lagging behind Apple and Amazon. “I think the performance will come back from Apple in 2021. It may seem numb for a company to run FAANG for three straight years, but I think this will actually happen. I think this has a trail of 200 U.S. dollar [per share]. “

A nurse prepares to administer the Pfizer-BioNTech COVID-19 vaccine at Guy’s Hospital in London, United Kingdom, on December 8, 2020.

Frank Augstein | Reuters

Doctors in the UK are pushing for health officials’ decision to change the schedule for Pfizer’s Covid-19 vaccinations, saying it will not “follow science”.

UK health officials said Wednesday they would prefer to give the first dose of vaccine to as many people as possible as soon as possible, which could delay the supply of those who received the second vaccine by up to 12 weeks. Pfizer’s Covid-19 vaccine developed with BioNTech recommends giving the second shot three weeks after the initial dose.

The decisions would also apply to the two-dose coronavirus vaccine developed by Oxford University and AstraZeneca, which the UK approved for emergency use on Wednesday. The first doses are expected to be launched next week and added to a Covid-19 immunization program launched by the UK in December with the Pfizer BioNTech vaccine.

“We have real and serious concerns about these sudden changes to the Pfizer vaccination regime,” the Doctors’ Association UK, a nonprofit advocacy group of voluntary health professionals, said in a tweet Thursday. “It undermines the consent process and doesn’t obey science at all.”

The organization said in a statement that the decision to change the regime is likely to be difficult given the pressure the country’s hospitals are facing from Covid-19 patients. However, the protection shown after just one dose is “considerably less” than with two shots.

Pfizer’s late-stage clinical studies showed that the vaccine was somewhat effective after the first dose was given. In documents released to the U.S. Food and Drug Administration in early December, data showed that at least 52% of the vaccine before the second dose and 82% in the combined group of people who took one or two doses, was effective.

However, Pfizer and Moderna’s vaccines have been shown to be at least 94% effective when given in two doses about a month apart.

Pfizer, however, pushed back the UK’s decision in a statement to CNBC on Thursday, saying its large clinical trials had tested a 21-day interval. Clinical studies have shown that two doses three weeks apart has been shown to provide maximum effectiveness, the company said.

“The safety and efficacy of the vaccine were not assessed according to different dosing schedules, as the majority of study participants received the second dose within the window specified in the study design,” Pfizer said.

Separately, the UK government said that the advice of the Joint Vaccination and Immunization Committee, which advises it on vaccination programs, “would ensure that more at-risk people receive meaningful protection from a vaccine in the coming weeks and months”.

This would help reduce the number of deaths and ease pressure on the country’s hospitals, especially as the country battles a new, faster-spreading variant of the virus.

“The committee recommends prioritizing the delivery of the first vaccine dose first, as it is most likely to have greater public health impacts in the short term and reduce the number of preventable deaths from COVID-19,” the advisory committee said in a statement Thursday.

Pfizer’s vaccine doses have been launched in the UK for over three weeks, and around 600,000 people have already received their first doses of the medicine according to recent government statistics.

While the decision is ultimately up to health officials, it will be “critical” to monitor alternative schedules to “ensure that each recipient is given the maximum possible protection, which means immunization with two doses of the vaccine,” Pfizer said.

– CNBC’s Matt Clinch, Holly Ellyatt, Steve Kopack and Berkeley Lovelace Jr. contributed to this report.

A pharmacist dilutes the Pfizer COVID-19 vaccine as he prepares it for administration to staff and residents at Goodwin House Bailey’s Crossroads, a senior community in Falls Church, Virginia, on December 30, 2020.

Brendan Smialowski | AFP | Getty Images

Dozens of people in West Virginia were mistakenly given Regeneron’s Covid-19 antibodies instead of the Moderna vaccine, the West Virginia National Guard said Thursday.

According to the state’s National Guard, 42 people received the intravenous treatment at a Boone County Department of Health vaccination clinic. The National Guard said it learned of the mistake on Wednesday.

Everyone who received the antibody treatment instead of the vaccine, which is given through a shot in the arm, has been contacted, Julie Miller, a Boone County Health Department administrator, told CNBC via email. She added, “We don’t think there is any risk of harm.”

Regeneron’s monoclonal antibody treatment, which must be given via an IV drip, is seen as a promising treatment for Covid-19 – especially if given early in the course of the infection. But the West Virginia mix-up is just one example of the confusion in the rush to distribute the vaccine to tens of millions of people. The rollout was slower than expected and was characterized by logistical challenges.

“It was determined that this was an isolated incident,” Miller said. “All those affected will be offered the COVID-19 vaccine today.”

She said the health department will work closely with the state National Guard and the Department of Health and Human Resources to review their policies and procedures.

Miller did not provide details on what caused the mix-up.

Representatives from the West Virginia National Guard and the West Virginia Governor’s Office did not respond to CNBC’s request for further comment on the occurrence of the error.

Maj. Gen. James Hoyer, adjutant general of the West Virginia National Guard, said in a statement that his forces “acted immediately” to correct the mistake as soon as they found out what happened. “We immediately reviewed and strengthened our logs to improve our sales process and prevent this from happening again,” he said in a statement.

He added that the state will continue to promote the vaccine “to save more lives every day”.

Dr. Clay Marsh, the state’s Covid-19 tsar, noted in a statement that the Regeneron treatment mistakenly given in place of the vaccine is the same product “that was given to President Trump when he became infected”.

“Although this injection is not harmful, it has replaced the vaccine,” he said. “However, this event provides an important opportunity for our leadership team to review and improve the safety and vaccination process for every West Virginian.”